undamentalytics Newsletter
Sign in

Azenta, Inc. revenue

Azenta, Inc.'s revenue was $594m in fiscal 2025, up 3.6% on the year before. Since fiscal 2009 ($219m) it has grown at a compound 6.4% a year. Over the last twelve months it was $614m.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2009Sept 20092010Sept 20102011Sept 20112012Sept 20122013Sept 20132014Sept 20142015Sept 20152016Sept 20162017Sept 20172018Sept 20182019Sept 20192020Sept 20202021Sept 20212022Sept 20222023Sept 20232024Sept 20242025Sept 2025LTMJun 2026
Revenue219593688489422483553434527632334389514555551573594614
Growth on the year before—+171.1%+16.0%−28.9%−13.6%+14.3%+14.5%−21.5%+21.5%+19.7%−47.1%+16.3%+32.2%+8.1%−0.7%+4.0%+3.6%—
Gross profit−6166223159132167189157199246135172244256239255270270
Gross margin−2.7%28.0%32.4%32.6%31.3%34.7%34.2%36.1%37.7%39.0%40.3%44.3%47.5%46.0%43.4%44.4%45.5%44.0%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Where the revenue comes from

Fiscal year to September 30, 2025
Segments
Line of business Revenue Share YoY
Sample Management Solutions $325M 54.7% ▲ 1.8%
Core Products $198M 60.9% ▲ 0.6%
Sample Repository Solutions $127M 39.1% ▲ 3.7%
Multiomics $269M 45.3% ▲ 5.8%
Products and services
Line of business Revenue Share YoY
Services $421M 70.8% ▲ 5.2%
Products $173M 29.2% ▼ 0.3%
Geography
Region Revenue Share YoY
United States $365M 61.5% 0.0%
Europe $107M 18.1% ▲ 12.8%
China $58.3M 9.8% ▲ 0.2%
United Kingdom $35.4M 6.0% ▲ 30.1%
Asia Pacific $23.3M 3.9% ▲ 9.2%
Other $4.4M 0.7% ▼ 31.5%

From Azenta, Inc.'s 10-K filed December 4, 2025, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Revenue against peers

Life Sciences Tools & Services: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Azenta, Inc. $614m 4.9% -0.9%
10x Genomics, Inc. $617m -4.3% 2.8%
Veracyte, Inc. $562m 17.3% 19.6%
Neogenomics Inc $788m 11.1% 11.1%
Repligen Corp $806m 13.8% 7.3%
Twist Bioscience Corp $432m 19.2% 22.4%

Compare with peers

Head to head: AZTA vs TXGAZTA vs VCYTAZTA vs NEOAZTA vs RGEN

More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies

Figures from Azenta, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Azenta, Inc.